On Wednesday, the U.S. Food and Drug Administration (FDA) approved Tenpoint Therapeutics Ltd.’s Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop for presbyopia in adults.Presbyopia, the gradual loss of near vision that typically begins around age 45, affects about two billion people globally and 128 million people in the U.S.Yuvezzi is expected to be broadly commercially available in the U.S. in the second q ...